← Leaderboards
Margaret C. Fang
University Of California, San Francisco
$5,446,677
Attributed
$5,716,971
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $987K · FY2006–22$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,716,971 · 4
By mechanism
R01$3,579,608 · 1
K23$865,771 · 1
K24$731,004 · 1
R21$540,588 · 1
Top collaborators
- Janice B Schwartz3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- John Matthew Inadomi$9,020,701
- Adam Wayne Carrico$20,345,043
- Donna M. Ferriero$20,040,301
- Alison M El Ayadi$8,776,923
- Katerina A Christopoulos$10,490,512
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseHemorrhageAnticoagulantsAnticoagulationWarfarinMonitorCostMorbidity - Disease RateElderlyStroke PreventionAtrial FibrillationPreventionPharmaceutical PreparationsDoseEnrollmentChronicOlder PatientSafetyCaliforniaSan FranciscoProgramsCohortResearch PersonnelCareer
Grant awards (19)
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients$121,834
K24 · FY2022 · HL · contact PI
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients$121,834
K24 · FY2022 · HL · contact PI
Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients$161,500
R21 · FY2021 · AG
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients$121,834
K24 · FY2021 · HL · contact PI
Supplement to Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients$96,900
R21 · FY2021 · AG
Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients$282,188
R21 · FY2020 · AG
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients$121,834
K24 · FY2020 · HL · contact PI
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients$121,834
K24 · FY2019 · HL · contact PI
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients$121,834
K24 · FY2018 · HL · contact PI
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism$536,641
R01 · FY2014 · HL · contact PI
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism$705,006
R01 · FY2013 · HL · contact PI
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism$751,871
R01 · FY2012 · HL · contact PI
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism$769,337
R01 · FY2011 · HL · contact PI
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism$816,753
R01 · FY2010 · HL · contact PI
Risks of Warfarin for Elders with Atrial Fibrillation$170,251
K23 · FY2010 · AG · contact PI
Risks of Warfarin for Elders with Atrial Fibrillation$161,843
K23 · FY2009 · AG · contact PI
Risks of Warfarin for Elders with Atrial Fibrillation$183,670
K23 · FY2008 · AG · contact PI
Risks of Warfarin for Elders with Atrial Fibrillation$174,967
K23 · FY2007 · AG · contact PI
Risks of Warfarin for Elders with Atrial Fibrillation$175,040
K23 · FY2006 · AG · contact PI